世界の眼科医薬品市場予測:網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬...市場調査レポートについてご紹介

【英文タイトル】Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Eye: An Overview of Its Structure and Function
2.3 The Global Burden of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: the ‘Silent Thief of Sight’
2.5.1 A Classification of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors for Glaucoma
2.5.3 Diagnosis of Glaucoma
2.5.4 Drug Treatment of Glaucoma
2.5.5 Laser Treatment and Surgery for Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors for AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis of Diabetic Retinopathy
2.7.2 Treatment of Diabetic Retinopathy
2.8 Ocular Allergy and Allergic Conjunctivitis
2.8.1 Diagnosis of Ocular Allergy
2.8.2 Treatment of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Scope of this Report
2.14 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2014-2024
3.1 The World Ophthalmic Drugs Market in 2013
3.1.1 Leading Ophthalmic Drugs
3.1.2 Leading Companies in the Ophthalmic Drugs Market
3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024
3.3 Retinal Disorder Drugs Lead the World Ophthalmic Drugs Market
3.4 How Will Segmental Market Shares Change to 2024?
3.4.1 World Ophthalmic Drugs Market: Drivers and Restraints 2014-2024

4. Leading National Markets 2014-2024
4.1 Geographical Breakdown of the World Ophthalmic Drugs Market
4.2 World Ophthalmic Drugs Market: National Markets Forecast 2014-2024
4.2.1 How Will National Market Shares Change to 2024?
4.3 The US Ophthalmic Drugs Market 2014-2024
4.3.1 US Ophthalmic Drugs Market Forecast 2014-2024
4.3.2 US Ophthalmic Drugs Market: Trends and Developments
4.3.2.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2.2 A US Biosimilars Market?
4.4 Japanese Ophthalmic Drugs Market 2014-2024
4.4.1 Japanese Ophthalmic Drugs Market Forecast 2014-2024
4.4.2 Japanese Ophthalmic Drugs Market: Trends and Developments
4.4.2.1 The Cost of Treatment in Japan
4.5 Chinese Ophthalmic Drugs Market 2014-2024
4.5.1 Chinese Ophthalmic Drugs Market Forecast 2014-2024
4.5.2 Chinese Ophthalmic Drugs Market: Trends and Developments
4.5.2.1 Expansion of Healthcare Coverage and Reimbursement
4.5.2.2 Price Controls and the Anhui Model
4.6 EU5 Ophthalmic Drugs Market 2014-2024
4.6.1 German Ophthalmic Drugs Market Forecast 2014-2024
4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024
4.6.3 UK Ophthalmic Drugs Market Forecast 2014-2024
4.6.4 Italian Ophthalmic Drugs Market Forecast 2014-2024
4.6.5 Spanish Ophthalmic Drugs Market Forecast 2014-2024
4.7 Brazilian Ophthalmic Drugs Market 2014-2024
4.7.1 Brazilian Ophthalmic Drugs Market Forecast 2014-2024
4.7.2 Brazilian Ophthalmic Drugs Market: Trends and Developments
4.7.2.1 Increasing Access to Medicines
4.8 Russian Ophthalmic Drugs Market 2014-2024
4.8.1 Russian Ophthalmic Drugs Market Forecast 2014-2024
4.8.2 Russian Ophthalmic Drugs Market: Trends and Developments
4.8.2.1 Pharma2020, Healthcare and Industry Reform
4.9 Indian Ophthalmic Drugs Market 2014-2024
4.9.1 Indian Ophthalmic Drugs Market Forecast 2014-2024
4.9.2 Indian Ophthalmic Drugs Market: Trends and Developments
4.9.2.1 Drug Prices Control Order 2013
4.9.2.2 Expansion of Healthcare Provision
4.10 Mexican Ophthalmic Drugs Market 2014-2024
4.10.1 Mexican Ophthalmic Drugs Market Forecast 2014-2024
4.10.2 Mexican Ophthalmic Drugs Market: Trends and Developments
4.10.2.1 Lupin Acquires Laboratorios Grin, Entering the Mexican Market
4.10.2.2 Seguro Popular: Mexican Healthcare Reform
4.10.2.3 International Interest in Mexico

5. Retinal Disorder Drugs Market 2014-2024
5.1 Retinal Disorder Drugs: the Rise of Anti-VEGF Therapy
5.2 Leading Retinal Disorder Drugs in 2013
5.3 Retinal Disorder Drugs: Market Forecast 2014-2024
5.4 Market Share of Leading Retinal Disorder Drugs to 2024
5.5 Retinal Disorder Drugs: Trends and Developments
5.5.1 Lucentis Dominates the Retinal Disorder Drugs Market
5.5.2 Roche and Novartis Fined Over Lucentis-Avastin Collusion
5.5.3 Requiring Avastin Use in AMD?
5.5.4 Novartis Licenses Ophthotech’s Fovista
5.5.5 Jetrea Launch Disappoints Analysts
5.5.6 Conbercept Approved in China
5.5.7 Drug/Device Combination Products Entering the Market
5.5.8 Advances in Regenerative Medicine
5.6 Lucentis (ranibizumab, Roche/Novartis)
5.6.1 Lucentis: Sales Forecast 2014-2024
5.6.2 Less Frequent Dosing Approved in US
5.6.3 New Indications for Lucentis
5.6.4 Lucentis/Fovista Combination Therapy?
5.7 Eylea (aflibercept, Regeneron/Bayer/Santen)
5.7.1 Eylea: Sales Forecast 2014-2024
5.7.2 The Comparative Efficacy of Eylea
5.7.3 Combination Therapy with Eylea and a PDGFR-beta Inhibitor
5.8 Avastin (bevacizumab, Roche)
5.8.1 Avastin: Sales Forecast 2014-2024
5.8.2 Compounding Pharmacies and Safety Risks
5.9 Visudyne (verteporfin, Valeant/Novartis)
5.9.1 Visudyne: Sales Forecast 2014-2024
5.10 Jetrea (ocriplasmin, ThromboGenics/Novartis)
5.10.1 Jetrea: Sales Forecast 2014-2024
5.10.2 Potential Acquisition of ThromboGenics?
5.10.3 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
5.11 Other Retinal Disorder Drugs
5.11.1 Iluvien (fluocinolone implant, Alimera Sciences)
5.11.2 Ozurdex (dexamethasone implant, Allergan)

6. Allergic, Inflammatory and Infective Drugs Market 2014-2024
6.1 Allergic, Inflammatory and Infective Drugs: Introduction
6.2 Allergic, Inflammatory and Infective Drugs: Submarket Breakdown
6.3 Leading Allergic, Inflammatory and Infective Drugs in 2013
6.4 Allergic, Inflammatory and Infective Drugs: Market Forecast 2014-2024
6.5 Market Share of Leading Allergic, Inflammatory and Infective Drugs to 2024
6.6 Allergic, Inflammatory and Infective Drugs: Trends and Developments
6.6.1 Growth Prospects in 2014-2024
6.6.2Lupin Launches Generic Zymaxid
6.6.3 New Topical NSAIDs Launched: Prolensa and Ilevro
6.7 Patanol and Pataday (olopatadine, Alcon)
6.7.1 Patanol: Sales Forecast 2014-2024
6.7.2 Pataday: Sales Forecast 2014-2024
6.7.3 Generic Competition for Patanol/Pataday?
6.8 Vigamox (moxifloxacin, Alcon)
6.8.1 Vigamox: Sales Forecast 2014-2024
6.8.2 Generic Challenges to Vigamox
6.8.3 Moxeza: A Next-Generation Form of Vigamox
6.9 TobraDex (tobramycin/dexamethasone, Alcon)
6.9.1 TobraDex: Sales Forecast 2014-2024
6.9.2 TobraDex ST (Alcon/Novartis)
6.10 Bromday (bromfenac, Valeant)
6.10.1 Bromday: Sales Forecast 2014-2024
6.10.2 Prolensa: A New Formulation of Bromfenac
6.10.3 Competition from Ilevro/Nevanac
6.11 Cravit (levofloxacin, Santen)
6.11.1 Cravit: Sales Forecast 2014-2024
6.12 Acular (ketorolac, Allergan)
6.12.1 Acular: Sales Forecast 2014-2024
6.13 AzaSite (azithromycin, Akorn)
6.13.1 AzaSite: Sales Forecast 2014-2024

7. Glaucoma Drugs Market 2014-2024
7.1 Glaucoma: Prostaglandin Analogues Lead the Market
7.2 Leading Glaucoma Drugs in 2013
7.3 Glaucoma Drugs: Market Forecast 2014-2024
7.4 Market Share of Leading Glaucoma Drugs to 2024
7.5 Glaucoma Drugs: Trends and Developments
7.5.1 Revenues Threatened by Patent Expiration
7.5.2 Preservative-Free Formulation Trends
7.5.3 Innovation in Treatments for Glaucoma
7.5.4 Simbrinza Launched as First Beta-Blocker-Free Combination
7.6 Lumigan and Ganfort (bimatoprost, Allergan)
7.6.1 Lumigan and Ganfort: Sales Forecast 2014-2024
7.7 Xalatan and Xalacom (latanoprost, Pfizer)
7.7.1 Xalatan/Xalacom: Sales Forecast 2014-2024
7.8 Travatan/Travatan Z and DuoTrav (travoprost, Novartis)
7.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024
7.9 Alphagan/Alphagan P and Combigan (brimonidine, Allergan)
7.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024
7.10 Trusopt and Cosopt/Cosopt PF (dorzolamide, Merck)
7.10.1 Trusopt: Sales Forecast 2014-2024
7.10.2 Cosopt and Cosopt PF: Sales Forecast 2014-2024
7.11 Azopt (brinzolamide, Novartis)
7.11.1 Azopt: Sales Forecast 2014-2024
7.12 Tapros (tafluprost, Santen)
7.12.1 Tapros/Taflotan: Sales Forecast 2014-2024
7.13 Zioptan (tafluprost, Akorn)
7.13.1 Zioptan: Sales Forecast 2014-2024

8. Dry Eye Drugs Market 2014-2024
8.1 Dry Eye: Introduction
8.2 Leading Dry Eye Drugs in 2013
8.3 Dry Eye Drugs: Market Forecast 2014-2024
8.4 Market Share of Leading Dry Eye Drugs to 2024
8.5 Dry Eye Drugs: Trends and Developments
8.5.1 Will Generic Restasis Launch in 2014?
8.5.2 Intensive Research Focus on Dry Eye
8.5.3 Improving Diagnostic Tools
8.6 Restasis (ciclosporin, Allergan)
8.6.1 Restasis: Sales Forecast 2014-2024
8.7 Refresh Brand Products (Allergan)
8.7.1 Refresh Brand Products: Sales Forecast 2014-2024
8.8 Hyalein (hyaluronic acid, Santen)
8.8.1 Hyalein: Sales Forecast 2014-2024
8.9 Diquas (diaquafosol, Santen)
8.9.1 Diquas: Sales Forecast 2014-2024
8.10 Other Ophthalmic Drugs
8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)
8.10.2 Hetlioz: Sales Forecast 2014-2024

9. Leading Companies in the Ophthalmic Drugs Market
9.1 Novartis (Alcon)
9.1.1 Novartis: Ophthalmic Drugs Portfolio
9.1.2 Novartis: Sales Forecast 2014-2024
9.1.3 Novartis: Products in Development
9.1.4 Novartis: Recent Developments
9.1.4.1 Novartis Restructures Following Strategic Review
9.1.4.2 Novartis Licenses Ophthothech’s Fovista
9.2 Allergan
9.2.1 Allergan: Ophthalmic Drugs Portfolio
9.2.2 Allergan: Sales Forecast 2014-2024
9.2.3 Allergan: Products in Development
9.2.3.1 Novadur (Intravitreal Brimonidine Implant)
9.2.4 Allergan: Recent Developments
9.2.4.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.2.4.2 Prospects for Generic Restasis?
9.2.4.3 Allergan Rejects Valeant Bid
9.2.4.4 Allergan Considering Acquiring Shire?
9.3 Roche
9.3.1 Roche: Ophthalmic Drugs Portfolio
9.3.1.1 Lucentis: US Sales Forecast 2014-2024
9.3.2 Roche: Sales Forecast 2014-2024
9.3.3 Roche: Products in Development
9.4 Valeant
9.4.1 Valeant: Ophthalmic Drugs Portfolio
9.4.2 Valeant: Sales Forecast 2014-2024
9.4.3 Valeant: Products in Development
9.4.4 Valeant: Recent Developments
9.4.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
9.4.4.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals
9.5 Regeneron
9.5.1 Regeneron: Ophthalmic Drugs Portfolio
9.5.2 Regeneron: Sales Forecast 2014-2024


【レポート販売概要】

■ タイトル:世界の眼科医薬品市場予測:網膜疾患/アレルギー性炎症/緑内障/眼球乾燥症治療薬
■ 英文:Ophthalmic Drugs Market Forecast 2014-2024
Prospects for Leading Companies
■ 発行日:2014年6月
■ 調査会社:visiongain
■ 商品コード:VISG409051
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。